Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance

Amneal Pharmaceuticals, Inc.

2023-Q2 EPS reported $0.03 revenue$1,156,586,000

Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.
Adjusted net income $57M, adjusted EBITDA $146M (+9% YoY), adjusted diluted EPS $0.19.
Raising 2023 full year guidance following strong H1 performance.
Growth driven by Generics (complex portfolio, biosimilars), AvKARE expansion, and Specialty.
Company addressing U.S. drug shortages as one of largest domestic manufacturers.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Amneal Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $599 million, net income $12 million, EPS $0.08. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $599 million
Net income: $12 million
EPS: $0.08
Guidance: raised
Result: reported results

Exact text from the filing

AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Full Year Guidance ‒

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.